How U.S. Pharma Executives Are Accelerating China's Dominance in Biotech and Drug Development
In just three years, China's biopharmaceutical industry has risen from near irrelevance to dominance, with U.S. pharma leaders facilitating its growth...
In just three years, China's biopharmaceutical industry has risen from near irrelevance to dominance, with U.S. pharma leaders facilitating its growth...
The U.S. Supreme Court faces a request to restore mail-order access to mifepristone amid legal challenges. UCB acquires Candid Therapeutics for $2.2 b...